RAPT Therapeutics, Inc. (RAPT) Common Equity (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Common Equity for 5 consecutive years, with $95.5 million as the latest value for Q3 2024.
- Quarterly Common Equity fell 44.73% to $95.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $95.5 million through Sep 2024, down 44.73% year-over-year, with the annual reading at $147.0 million for FY2023, 40.03% down from the prior year.
- Common Equity hit $95.5 million in Q3 2024 for RAPT Therapeutics, down from $109.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $245.2 million in Q4 2022 to a low of $91.6 million in Q1 2021.
- Historically, Common Equity has averaged $160.3 million across 5 years, with a median of $167.8 million in 2022.
- Biggest five-year swings in Common Equity: soared 83.44% in 2021 and later plummeted 45.3% in 2024.
- Year by year, Common Equity stood at $104.2 million in 2020, then skyrocketed by 78.9% to $186.4 million in 2021, then skyrocketed by 31.54% to $245.2 million in 2022, then tumbled by 40.03% to $147.0 million in 2023, then plummeted by 35.05% to $95.5 million in 2024.
- Business Quant data shows Common Equity for RAPT at $95.5 million in Q3 2024, $109.2 million in Q2 2024, and $130.8 million in Q1 2024.